Quince Therapeutics, Inc. Common Stock

QNCXNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
16.75 USD
↘ 1.44 (7.92%)AT CLOSE (11:59 AM EDT)
16.63
↘ 0.12 (0.72%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
16.63
↘ 0.12 (0.72%)
🔴Market: CLOSED

Quince Therapeutics, Inc. Common Stock (QNCX) trades at $17.05 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jul 1, 2026.

Open?$18.00
High?$18.03
Low?$15.10
Prev. Close?$18.19
Volume?104.6K
Avg. Volume?1.4M
VWAP?$16.17
Rel. Volume?0.07x
Bid / Ask
Bid?$13.30 × 100
Ask?$19.05 × 100
Spread?$5.75
Midpoint?$16.18
Valuation & Ratios
Market Cap?17.8M
Shares Out?N/A
Float?15.3M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?1.14
EPS?-$36.97
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Themes
Biotech - Drug Development›Rare Disease Therapeutics
Employees
38
Market Cap
17.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.quincetx.com
Listed
2019-05-09
Address
611 GATEWAY BLVD., SUITE 273
SOUTH SAN FRANCISCO, CA 94080
Phone: 415-910-5717
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
40
Piotroski F-Score?0/9Weak
Altman Z-Score?-27.76Distress
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.18%High
Short Interest?2.0M
Days to Cover?3.3
Free Float15.3M
Avg Daily Volume601.7K
Settlement Date2026-06-15
Financial Health
Current Ratio?2.92Strong
Quick Ratio?2.92Strong
Cash Ratio?2.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
94
1.14CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-230.7%WEAK▾
ROA?
S&P
3
-135.8%WEAK▾
Cash Flow & Enterprise
FCF?$-37731000
Enterprise Value?$-373871
Fundamentals ratios updated end of day
MarketsMoversWatchlist